Dossier
Galderma
Coverage of Galderma in the Nexus archive.
- Galderma Slumps After FDA Turns Down Botox Rival Relfydess
Galderma's stock declined following the FDA's rejection of Relfydess, a Botox competitor. The decision negatively impacted the company's market performance.